Back

Geranylgeranylacetone as prevention for postoperative Atrial Fibrillation (GENIALITY trial)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Prediction of atrial fibrillation recurrences: still a challenge Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Kennedy Silva Ramos

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
How does artificial intelligence-derived electrocardiographic age and sex predict recurrence outcomes after atrial fibrillation catheter ablation?
Doctor H. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The role of pulmonary vein anatomy in predicting atrial arrhythmia recurrence after pulsed-field ablation
Mr M. Mutti (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The impact of atrial fibrillation progression on the epicardial adipose tissue volume: supporting 'AF begets EAT' theory
Doctor K. Shimojo (Ogaki, JP)
Abstract Slides Video
Presentation thumbnail
Common genetic variants associated with characteristics and clinical outcomes of atrial fibrillation: from a large population based registry (FinnGen)
Doctor A. Maan (Toledo, US)
Abstract Slides Video
Presentation thumbnail
Impact of low hemoglobin levels on arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation
Doctor Y. Matsunaga (Sakai, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Prediction of atrial fibrillation recurrences: still a challenge

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Dynamic change, not tonic activation, of the heart rate variability predicts onset of postoperative atrial fibrillation
thumbnail
Congress Presentation
Prophylactic colchicine to reduce VOM ethanol infusion related Pericarditis
thumbnail
Congress Presentation
Association of growth differentiation factor 15 and soluble suppression of tumorigenicity-2 with atrial high rate episodes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources